We're announcing CVD-001, Omic's first cardiovascular program—targeting lipoprotein(a), or Lp(a), one of the most validated but challenging targets in cardiovascular disease.

## The Lp(a) Opportunity

Lipoprotein(a) is a genetically determined cardiovascular risk factor:

- **Elevated in ~20% of the population**
- **Causes 2-3x increased risk** of heart attack and stroke
- **No approved therapies** despite decades of research
- **~200 million people** could benefit from Lp(a)-lowering treatment

Unlike LDL cholesterol, Lp(a) levels don't respond significantly to diet, exercise, or statins. Current approaches in development focus on RNA-based therapies, which require injection and have significant manufacturing complexity.

## Our AI's Discovery

Our AI Scientist analyzed multi-omics data to understand Lp(a) biology:

- **Mapped the complete Lp(a) biosynthesis pathway** from genomic and proteomic data
- **Identified novel intervention points** beyond the known targets
- **Discovered potential small molecule approaches** to Lp(a) reduction
- **Modeled patient subgroups** by mechanism of elevated Lp(a)

The key insight was finding a previously unexplored node in the pathway amenable to small molecule intervention.

## Why Small Molecules?

Current Lp(a) programs in development (like pelacarsen and olpasiran) are antisense oligonucleotides or siRNAs that require injection and have complex manufacturing. A small molecule Lp(a)-lowering drug would offer:

- **Oral dosing**: Much easier for patients
- **Lower cost**: Critical for a common chronic condition
- **Faster development**: Better-understood regulatory pathway
- **Combination potential**: Easy to combine with statins

## Program Status

CVD-001 is in early discovery:

- Target validated through genetic and computational analysis
- High-throughput screen completed with multiple hit series
- Early structure-activity relationship (SAR) studies underway
- Clear proof-of-concept experiments defined

## The Platform Advantage

CVD-001 demonstrates how our platform can rapidly enter new therapeutic areas:

1. **AI identifies opportunity** through systematic analysis
2. **Digital Patients model** the biology and predict responders
3. **AI chemistry** accelerates hit finding and optimization
4. **Integrated platform** enables lean, efficient programs

We went from "no cardiovascular program" to "validated target with hit compounds" in under 12 months.

* * *

_CVD-001 is in early discovery. For partnership inquiries, contact [partnerships@omic.ai](mailto:partnerships@omic.ai)_

Omic - Building Biological Superintelligence to End Disease